Morya Arvind Kumar, Nishant Prateek, Singh Arshi, Sinha Sony, Shah Ramesh Chandra
Department of Ophthalmology, All India Institute of Medical Sciences, Bibinagar, Telangana, India.
Department of Refractive Surgery, Uvea and Neuro-Ophthalmology, Akhand Jyoti Eye Hospital, Saran, Bihar, India.
Clin Ophthalmol. 2025 Apr 28;19:1387-1399. doi: 10.2147/OPTH.S521607. eCollection 2025.
This is the first study evaluating the visual outcomes of the novel Progressive Polyfocal Autofocus Pro intraocular lens (IOL) (Lifeline Medical Devices Pvt. Ltd. Aurangabad, India) and comparing them with Eyecryl Actv multifocal IOL (model DIYHS600ROH, Biotech Vision Care Pvt. Ltd. Ahmedabad, India) at the first and sixth weeks after implantation in Indian eyes.
A retrospective nonrandomized, comparative study was conducted based on hospital records of patients operated for cataract between January 2019 and January 2021 with bilateral implantation of one of the two presbyopia-correcting IOLs. Patients aged between 11 and 78 years, with preoperative astigmatism of 1 diopter or less and no other ocular disorders, were included. Visual acuity for distance, intermediate and near, refractive outcomes, contrast sensitivity, reading speed, depth of focus, patient satisfaction, and presence of optical phenomenon classically faced with conventional presbyopia-correcting IOLs were evaluated at 6 weeks postoperatively.
Of 104 eligible patients, intermediate visual acuity scores, reading speed, contrast sensitivity, depth of focus, and patient satisfaction were better with the Autofocus Pro IOL (all P<0.001). Negative dysphotopsias were absent in the Autofocus Pro group, whereas they were seen in about one-third of patients in the Multifocal group (P<0.001). Halos and glare were also significantly lower in the Autofocus Pro group. There was no difference in the distance and near visual acuity.
This study highlights superior clinical outcomes and patient satisfaction associated with Autofocus Pro IOLs compared to Multifocal IOLs, indicating their potential as a preferred choice for cataract surgery.
这是第一项评估新型渐进多焦点自动对焦人工晶状体（IOL）（印度奥兰加巴德Lifeline医疗设备私人有限公司）视觉效果的研究，并在印度患者植入后的第一周和第六周将其与Eyecryl Actv多焦点人工晶状体（型号DIYHS600ROH，印度艾哈迈达巴德Biotech视觉护理私人有限公司）进行比较。
基于2019年1月至2021年1月期间接受白内障手术且双眼植入两种老花眼矫正人工晶状体之一的患者的医院记录，进行了一项回顾性非随机对照研究。纳入年龄在11至78岁之间、术前散光1屈光度或更低且无其他眼部疾病的患者。在术后6周评估远距离、中距离和近距离视力、屈光结果、对比敏感度、阅读速度、焦点深度、患者满意度以及传统老花眼矫正人工晶状体常见的光学现象。
在104例符合条件的患者中，自动对焦人工晶状体组的中距离视力评分、阅读速度、对比敏感度、焦点深度和患者满意度更高（均P<0.001）。自动对焦人工晶状体组未出现负性 dysphotopsias，而多焦点组约三分之一的患者出现（P<0.001）。自动对焦人工晶状体组的光晕和眩光也明显更低。远距离和近距离视力无差异。
本研究强调了与多焦点人工晶状体相比，自动对焦人工晶状体具有更好的临床效果和患者满意度，表明其作为白内障手术首选的潜力。
